Twist Bioscience Corp. sees decrease in shares after Sei Investments Co. sells off over 8,000 shares during Q4 2020

Twist Bioscience Corp., a leader in the development of synthetic DNA manufacturing processes for biotechnology applications, recently saw a decrease in shares by 3.4% after the selling off of over 8,000 shares by Sei Investments Co. during Q4 2020. Sei Investments Co.’s most recent 13F filing revealed that it owned 251,213 shares of Twist Bioscience’s stock worth $5,981,000 at the end of the quarter.

Twist Bioscience’s unique semiconductor-based synthetic DNA manufacturing process has attracted attention from investors and research analysts alike. The company’s products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools.

In recent months, several research analysts have given their opinion on Twist Bioscience’s potential for success. Barclays reduced its target price to $20 from $32 per share on May 8th while Robert W. Baird cut its target price to $18 from $29 per share. The Goldman Sachs Group also decreased its price objective on the stock from $43 to $20 and assigned a “neutral” rating.

Despite these setbacks, the Bloomberg consensus rating for Twist Bioscience remains at “Moderate Buy” with four out of six analysts giving a buy rating for the stock. With operations across America, EMEA (Europe, Middle East and Africa), and APAC (Asia-Pacific), Twist Bioscience continues to lead in its field with innovative technologies that are projected to drive growth and deliver long-term value to shareholders.

Investors keen on investing in an industry that offers both innovations in technology as well as steady returns should consider investing in Twist Bioscience now while share prices remain low but poised for recovery and growth.

TWST

Buy

Updated on: 06/06/2023

Price Target

Current $16.19

Concensus $34.00


Low $32.00

Median $34.00

High $36.00

Show more

Social Sentiments

We did not find social sentiment data for this stock

Analyst Ratings

Analyst / firm Rating
Luke Sergott
Barclays
Buy
Evercore ISI Buy
Luke Sergott
Barclays
Buy

Show more

Title: Institutional Investors Make Significant Changes in Twist Bioscience Holdings


Twist Bioscience: Institutional Investors Make Changes to Their Positions

Twist Bioscience Co. has recently witnessed changes in the positions of its institutional investors. Royal Bank of Canada has grown its position in Twist Bioscience by 3.3% during the third quarter, owning now 9,025 shares of the company’s stock valued at $318,000 after purchasing an additional 291 shares during the period. Similarly, Captrust Financial Advisors increased its stake in shares of Twist Bioscience by 101.3% in the 2nd quarter, owning now 759 shares of the company’s stock valued at $27,000 after purchasing another batch of 382 shares.

In addition to this, Principal Financial Group Inc raised its holdings in Twist Bioscience by 2.5% investing for a total value of $430,000, while Arizona State Retirement System boosted its position in Twist Bioscience by 4.0% during the fourth quarter currently owning around $360,000 worth shares.

Investment firms continue to display interest in Twist Bioscience with another change announced today – Ameritas Investment Partners Inc has grown its holdings in Twist Bioscience by 16.0% since January and now owns 4,293 shares of the company’s stock valued at $212,000 after purchasing an additional 591 shares during this period.

In related news that ought to garner some attention among investors closely following movement trends like these for educational purposes; Twist Bioscience’s insider Dennis Cho could be seen acquiring as many as 10 thousand shares of TWST generating a transaction that was recorded on Wednesday May 10th and worth almost $132k netting Mr Cho just under five hundred thousand dollars ($386k) equity positive following his purchase when TWST closed Friday afternoon on NASDAQ.

Insiders’ ownership stands at almost twelve percent (11.8%) having established itself since its inception in 2013 as a developer of proprietary semiconductor-based synthetic DNA manufacturing processes. Its wide suite of products includes genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery and SARS-CoV-2 Tools making Twist Bioscience an alluring tech player in the life sciences research industry.

TWST opened at $16.31 on Monday and has been trading within a range that varies between its 52-week low of $11.46 and its 52-week high of $58.76. The firm’s fifty-day moving average is reported at $13.80 whilst the two-hundred day moving average stood at $20.13.

It should be noted that Twist Bioscience published its quarterly earnings report only last Friday May 5th which indicated a net loss of ($1.06) per share for the quarter, topping the consensus estimate by $0.03. Whilst Twist Bioscience may have had to endure negative returns on equity recently due to market volatility in some sectors, analysts among including its institutional investors believe that Tracklay’s reliance on market forecasts carries considerable weight despite potential risks for researchers working with DNA sequencing techniques to outline their own plans and this methodology is seen positively both in relation to others’ similar profiles or indeed even beyond this year when considering long-term investment objectives pursuing market leadership going forward..


Read more here: Source link